Compare CXAI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAI | ATOS |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 24.1M |
| IPO Year | 2020 | 2010 |
| Metric | CXAI | ATOS |
|---|---|---|
| Price | $3.87 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 5.8M | 55.0K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,583,000.00 | $1,758.00 |
| Revenue This Year | $33.54 | N/A |
| Revenue Next Year | $116.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.53 |
| 52 Week High | $4.88 | $7.56 |
| Indicator | CXAI | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 82.36 | 52.55 |
| Support Level | $0.23 | $0.58 |
| Resistance Level | N/A | $2.60 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | 0.47 | 0.04 |
| Stochastic Oscillator | 78.29 | 48.11 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.